Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Feasibility of CIK Cell Therapy in HCC After Tumor Resection
Sponsor: Royan Institute
Summary
This study tests whether it is safe and feasible to give patients with hepatocellular carcinoma (liver cancer) an infusion of their own (autologous) immune cells, called cytokine-induced killer (CIK) cells, after they have had surgery to remove their liver tumor. The patient's own blood cells are collected and grown in a laboratory to create the CIK cells, which are then given back to the patient through six intravenous infusions over about two months. Patients are followed for six months to check for side effects and early signs of whether the cancer returns.
Official title: Safety and Feasibility of Autologous Cytokine Induced Killer (CIK) Cells Infusion as an Adjuvant Therapy in Post Resection Hepatocellular Carcinoma (HCC) Patients
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
6
Start Date
2026-07
Completion Date
2028-07
Last Updated
2026-07-16
Healthy Volunteers
No
Conditions
Interventions
Autologous Cytokine-Induced Killer (CIK) Cells
PBMCs are collected from the patient, expanded ex vivo for 14-21 days under GMP conditions administered as 6 intravenous infusions (weeks 0, 1, 2, then weeks 4, 6, 8) following release testing for sterility, viability, and phenotype.
Locations (1)
Liver Transplant and Surgery Research Center, Imam Khomeini Hospital, Tehran University of Medical Sciences
Tehran, Tehran Province, Iran